Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Inflammatory Bowel Disease
•
Gastroenterology
When do you consider de-escalation from combination therapy with anti-TNFs and thiopurines to monotherapy with anti-TNFs in patients with IBD?
Answer from: at Academic Institution
I withdraw the thiopurine if after 1 year the patient has achieved the goals of care.
Sign in or Register to read more
25838
Related Questions
In patients with longstanding UC or Crohn's colitis, would you extend the interval of surveillance colonoscopy to longer than 3 years if they have had little inflammatory disease over the years and no other factors to increase their risk (ie, history of polyps, history of dysplasia, or family history)?
How would you manage active non-stricturing, non-fistulizing moderate ileal Crohn’s disease in patients on Natalizumab with well-managed multiple sclerosis?
Would you consider chemo-RT for duodenal adenocarcinoma s/p resection with at least 1 cm positive margin in a patient with a history of Crohn's disease?
Would you start a biologic without a tissue diagnosis in a young male presenting with recurrent small bowel obstruction and MRE showing distal ileitis, which was unable to be reached despite repeat colonoscopy?
In a patient with well-controlled ulcerative colitis on tofacitinib for several years, would you consider switching to upadacitinib for a more favorable side effect profile?
What are your vaccine recommendations while patients are on biologics?
How would you approach the treatment of an SLE patient with refractory mucocutaneous ulcerations and lichenoid skin eruption despite treatment with MMF, Aza, Benlysta, Saphnelo, Rituximab, and JAK inhibitors?
What is your advice to patients with IBD who are on biologic therapies and planning for pregnancy?
When and how should we use biomarkers (i.e., CRP, stool calprotectin, mAb levels) to guide or optimize medical management of Crohn’s disease or ulcerative colitis?
After confirming the patient is not on NSAIDs, how do you approach acute ileitis on biopsies in a patient without symptoms or with only mild loose stools?